Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00451997 · ClinicalTrials.gov registry record · Phase 2
Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00451997: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00451997 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00451997, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if the combination of Gleevec (imatinib mesylate) and low doses of Cytarabine (ara-C) may help to control leukemia while causing fewer side effects than standard high dose chemotherapy.
Interventions
- DRUG Gleevec
- DRUG Ara-C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2004-03 |
| Est. Completion | 2007-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00451997
The ClinicalTrials.gov registry entry for NCT00451997 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gleevec is the first listed.
NCT00451997 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00451997 about?
NCT00451997 is a clinical study titled "Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes". The goal of this clinical research study is to learn if the combination of Gleevec (imatinib mesylate) and low doses of Cytarabine (ara-C) may help to control leukemia while causing fewer side effects than standard high dose chemotherapy.
What is the current status of trial NCT00451997?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2004-03. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00451997?
The interventions under investigation include: Gleevec (DRUG), Ara-C (DRUG).
Who is sponsoring clinical trial NCT00451997?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.